Details About Generic Salt ::  Didanosi

Main Medicine Class:: Anti-infective,Antiviral   

(die-DAN-oh-SEEN)

Videx

Class: Anti-infective/Antiviral

Drugs Class ::

 Action Inhibits replication of HIV by interfering with DNA synthesis.

Indications for Drugs ::

 Indications Advanced HIV infection in patients with intolerance or significant clinical or immunologic deterioration during zidovudine therapy.

Drug Dose ::

 Route/Dosage

ADULTS (< 60 KG): PO 125 mg (as 2 tablets) or 167 mg (powder for suspension q 12 hr. ADULTS (> 60 KG): PO 200 mg (as 2 tablets) or 250 mg (powder for suspension) q 12 hr. CHILDREN: PO 100 to 300 mg/m²/day bid as oral powder for suspension. Reduce dose by 20% for tablets. CHILDREN < 1 yr should receive 1-tablet dose; those > 1 yr should get a 2-tablet dose.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category B. Lactation: Undetermined. Special diets: Each tablet contains 22.5 mg phenylalanine and 265 mg sodium; single-dose powder packet contains 1380 mg sodium. Mutagenesis: May be genotoxic. Renal or hepatic impairment: Dosage may need to be reduced. Hepatic failure has occurred in pediatric patients. Pancreatitis: Major toxicity; has been fatal. Should be considered if patient develops abdominal pain, nausea, vomiting or lab test abnormalities. Peripheral neuropathy: Occurs frequently; may be dose-related.

Drug Side Effects ::

 Adverse Reactions

CNS: Peripheral neuropathy; asthenia; headache; pain; myopathy; seizure. DERM: Rash; pruritis; alopecia; sweating. EENT: Retinal depigmentation. GI: Pancreatitis; diarrhea; abdominal pain; nausea; vomiting; anorexia; dry mouth. HEMA: Leukopenia, thrombocytopenia, granulocytopenia, and decreased hemoglobin. HEPA Hepatic failure. RESP: Pneumonia; dyspnea; cough; epistaxis; hypoventilation; sinusitis. OTHER: Chills, fever; infection; sarcoma.

Drug Mode of Action ::  

 Action Inhibits replication of HIV by interfering with DNA synthesis.

Drug Interactions ::

 Interactions

Drugs that cause peripheral neuropathy or pancreatitis: Increased risk of these toxicities. Food: Reduces absorption of didanosine by as much as 50%. Fluoroquinolones, tetracyclines: Do not administer within 2 hr of didanosine. Ketaconazole, dapsone, and other drugs whose absorption can be affected by gastric acidity: Administer ³ 2 hr before didanosine.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note renal or liver impairment, history of pancreatitis and prior response to zidovudine therapy.
• Ensure that liver and renal function tests are obtained before beginning drug therapy and repeat periodically.
• Notify physician if diarrhea develops in patient receiving oral solution. Switching to tablets may alleviate symptoms.
• If patient has abdominal pain, nausea or vomiting, or has elevated amylase or liver function test results, contact physician and withhold drug until pancreatitis can be excluded.
• Observe for symptoms of peripheral neuropathy (distal numbness, tingling, pain in feet or hands) or evidence of opportunistic infections. Notify physician if these occur.
• Monitor uric acid levels closely for possible asymptomatic hyperuricemia.
• Monitor body temperature to detect possible infection.
• Document any change in vision in pediatric patients. Dilated examination should be performed every 6 mo.

Drug Storage/Management ::

 Administration/Storage

• Give on an empty stomach.
• Have patients chew tablets or manually crush or disperse tablets in water (2 tablets per 1 oz water).
• When dispersing tablets in water, stir until uniform dispersion occurs, then have patient drink entire amount immediately.
• When preparing buffered powder for oral suspension, do not use fruit juice or other acid-containing liquid. Stir until completely dissolved in 4 oz liquid, then have patient drink entire amount immediately.
• Pediatric powder for oral suspension is first mixed with purified water to obtain concentration of 20 mg/ml, then mixed with antacid to obtain final concentration of 10 mg/ml.
• Pediatric oral solution admixture may be stored for up to 30 days if refrigerated. Shake well before use.

Drug Notes ::

 Patient/Family Education

• Advise patient to take drug on empty stomach and to chew or crush tablets.
• Inform patient that drug does not completely eliminate HIV virus and therefore does not reduce risk of transmitting HIV. Appropriate precautions must be continued.
• Emphasize that drug does not cure AIDS or AIDS-related complex (ARC) and that significant changes in health should be reported to physician.
• Instruct patient to report these symptoms to physician: abdominal pain, diarrhea, nausea, vomiting, tingling pain or numbness in hands or feet, fever, sore throat or flu-like symptoms.
• Advise patient to avoid intake of alcoholic beverages or taking otc medications without notifying physician.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.